Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16621276 | 0.92 | TSHR (0.46) | TSHRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL10610012 | 0.87 | MAPT (0.51) | TSHRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL10610015 | 0.87 | MAPT (0.51) | TSHRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL10610005 | 0.87 | MAPT (0.51) | TSHRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL14524411 | 0.86 | ZDHHC7 (0.50) | TSHRKMT2AALDH1A1 | |
| SCHEMBL8555676 | 0.86 | TSHR (0.46) | TSHRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL10613735 | 0.85 | TSHR (0.45) | TSHRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL1673057 | 0.85 | TSHR (0.45) | TSHRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL7258072 | 0.84 | KMT2A (0.51) | TSHRMAPTRAB9AKMT2AMEN1 | |
| SCHEMBL5692057 | 0.83 | ALDH1A1 (0.50) | TSHRMAPTRAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5064956-A | Process for preparing mono-n-alkylated polyazamacrocycles | THE DOW CHEMICAL COMPANY (US) | 1991-11-12 | — | — | US | claimed |
| WO-1990007261-A2 | PROCESS FOR PREPARING MONO-N-ALKYLATED POLYAZAMACROCYCLES | THE DOW CHEMICAL COMPANY (US) | 1990-07-12 | — | — | WO | claimed |
| EP-0374929-A1 | Process for preparing mono-n-alkylated polyazamacrocycles | THE DOW CHEMICAL COMPANY (US) | 1990-06-27 | — | — | EP | claimed |
| US-20120095185-A1 | PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE | NORDION (CANADA) INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| US-20120095185-A1 | PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE | NORDION (CANADA) INC. (CA) | 2012-04-19 | — | — | US | disclosed |
| WO-2012037648-A1 | PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE | NORDION (CANADA) INC. (CA) | 2012-03-29 | — | — | WO | disclosed |
| US-7306785-B2 | Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using | GENERAL ELECTRIC COMPANY (US) | 2007-12-11 | — | — | US | disclosed |
| US-7306785-B2 | Multifunctional cross-bridged tetraaza macrocyclic compounds and methods of making and using | GENERAL ELECTRIC COMPANY (US) | 2007-12-11 | — | — | US | disclosed |
| US-20070098643-A1 | Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| US-20070098643-A1 | Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates | GUERBET (FR) | 2007-05-03 | — | — | US | disclosed |
| US-20060239926-A1 | Specific high-relaxivity compounds | GUERBET (FR) | 2006-10-26 | — | — | US | disclosed |
| EP-1635877-A2 | SPECIFIC HIGH-RELAXIVITY CONJUGATE COMPOUNDS FOR MAGNETIC RESONANCE IMAGING | GUERBET (FR) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004112839-A2 | SPECIFIC HIGH-RELAXIVITY CONJUGATE COMPOUNDS FOR MAGNETIC RESONANCE IMAGING | GUERBET (FR) | 2004-12-29 | — | — | WO | disclosed |
| EP-0374929-B1 | Process for preparing mono-N-alkylated polyazamacrocycles | DOW CHEMICAL CO (US) | 1998-03-25 | — | — | EP | disclosed |
| US-5064956-A | Process for preparing mono-n-alkylated polyazamacrocycles | THE DOW CHEMICAL COMPANY (US) | 1991-11-12 | — | — | US | disclosed |
| WO-1990007261-A2 | PROCESS FOR PREPARING MONO-N-ALKYLATED POLYAZAMACROCYCLES | THE DOW CHEMICAL COMPANY (US) | 1990-07-12 | — | — | WO | disclosed |
| EP-0374929-A1 | Process for preparing mono-n-alkylated polyazamacrocycles | THE DOW CHEMICAL COMPANY (US) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070098643-A1 | Oligomers of gadolinium chelates, their applicationascontrast products in magnetic resonance imaging and their synthesis intermediates | MGAT2, MGAT1, MGAT3 | TSHR 2567/4885MAPT 238/4885RAB9A 2062/4885 |
| US-20060239926-A1 | Specific high-relaxivity compounds | TNNC1, TNNT2, TNNI3 | TSHR 4329/4885MAPT 700/4885RAB9A 3531/4885 |
| US-20120095185-A1 | PROCESS FOR CHELATING COPPER IONS USING CB-TE2A BIFUNCTIONAL CHELATE | TBCA, UBE2G2, COPG2 | TSHR 807/4885MAPT 2781/4885RAB9A 821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.